Moody Lynn Lieberson & Walker 13F: Exits NBIX Stake

Moody Lynn Lieberson & Walker completely exited its position in Neurocrine Biosciences, Inc. (NasdaqGS: NBIX), selling off all 12,591 shares it previously held. The move was revealed in a Form 13F filing with the Securities and Exchange Commission on October 14, 2026. Because 13F filings look backward at holdings from the end of the reported period, this document shows the fund's status at that time and may not reflect its current portfolio.

Inside Moody Lynn Lieberson & Walker's Neurocrine Biosciences Trade

The fund sold out its entire stake, reducing its share count from 12,591 shares to zero. This total liquidation means the firm no longer holds any investment in the specialty pharmaceutical company.

Other Institutional Activity in Neurocrine Biosciences

Other large money managers adjusted their positions in the drug maker during the reporting period. Blackrock Inc. grew its holdings by 326,594 shares, ending with 13,711,607 shares worth about $1,860,802,278 after a 2.4% increase. JPMORGAN CHASE & CO added 956,699 shares for a 17.6% boost, finishing with 6,398,674 shares valued at roughly $868,364,091. Dodge & Cox Inc. grew its holdings by 123,425 shares, ending with 5,584,707 shares worth about $757,900,624 after a 2.3% increase. Vanguard Portfolio Management LLC added 247,664 shares for a 5.2% increase, closing the period with 4,974,083 shares valued at roughly $675,032,837. Vanguard Capital Management LLC grew its holdings by 33,388 shares, finishing with 4,545,339 shares worth about $616,847,986 after a 0.7% bump.

Neurocrine Biosciences, Inc. Stock Down 0.8%

Neurocrine Biosciences shares recently traded around $135.90 as of October 16, 2026. The stock sits below its 50-day moving average and below its 52-week high of $186.12.

Recent Earnings

Neurocrine Biosciences reported trailing-twelve-month revenue of $3.37 billion alongside earnings of $6.82 per share. The company posted a net profit margin of 20.9% and a return on equity of 22.1%. Its next earnings report is scheduled for November 2, 2026.

Insider Buying and Selling at Neurocrine Biosciences, Inc.

Company insiders executed several stock sales in recent months. Director Leslie V. Norwalk sold 1,250 shares on July 28, 2026, at an average price of $182.01 for a total of $227,508. Officer Eric S. Benevich disposed of 2,154 shares on September 9, 2026, at $154.61 per share, totaling $333,030. Officer David Warren Boyer sold 826 shares on September 14, 2026, at $157.45 each, worth $130,051. Chief Financial Officer Matthew C. Abernethy unloaded 2,311 shares on September 14, 2026, at an average price of $157.20 for a total of $363,285.

Analysts Set New Price Targets

Wall Street research firms have actively adjusted their views on the stock. On September 3, 2026, Citigroup maintained its Buy rating with a target of $253.00, moving up from $249.00. RBC Capital reiterated its Outperform rating with a $198.00 target on September 8, 2026. Morgan Stanley maintained an Equal-Weight rating and lifted its target from $182.00 to $183.00 on September 11, 2026. UBS maintained its Buy rating on September 29, 2026, while lowering its target from $231.00 to $214.00. BMO Capital maintained a Market Perform rating on October 12, 2026, cutting its target to $150.00 from $164.00. Overall, the stock carries a consensus strong buy recommendation from 29 analysts, with a mean price target of $206.81.

About Neurocrine Biosciences

Headquartered in San Diego, California, Neurocrine Biosciences discovers, develops, and markets pharmaceutical treatments for neurological, endocrine, psychiatric, and immunological conditions. The company employs roughly 2,500 people and focuses on specialized therapies for patients with high unmet medical needs.

Bottom Line

Investors will be watching Neurocrine Biosciences closely as its next earnings update approaches on November 2, 2026. Institutional ownership trends and upcoming regulatory updates will also shape market sentiment for the drug maker going forward. This filing reflects past portfolio adjustments and may not represent Moody Lynn Lieberson & Walker's current holdings. Keep in mind that 13F filings are backward-looking: they show holdings as of the end of the reporting quarter and may not represent the fund's current position.